Cadrenal Therapeutics (CVKD) Chief Medical Officer James Ferguson to step down July 31, 2026

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Cadrenal Therapeutics, Inc. reported that its Chief Medical Officer, Dr. James J. Ferguson III, has decided to resign from his position. He notified the Board on July 7, 2026, and his resignation will be effective on July 31, 2026, referred to as the Separation Date. Cadrenal is conducting a search to identify a new Chief Medical Officer to lead its medical and clinical functions. The company and Dr. Ferguson are negotiating the terms of his departure and expect to enter into a separation agreement and release at a later time.

Positive

None.

Negative

Chief Medical Officer resignation may introduce leadership and execution risk in clinical and regulatory activities until a successor is appointed and established.

Insights

Key medical leader resigns; transition risk until a successor is named.

The resignation of Chief Medical Officer Dr. James J. Ferguson III, effective on July 31, 2026, removes a senior clinical leader from Cadrenal Therapeutics. For a therapeutics company, the CMO role is central to clinical strategy, trial oversight, and regulatory interactions.

The company states that a search is underway for a replacement and that it expects to finalize a separation agreement and release with Dr. Ferguson. Until a new CMO is appointed and fully integrated, there can be execution risk around ongoing and planned clinical and regulatory activities.

8-K Event Classification

2 items: 5.02, 9.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Board notification date: July 7, 2026 Separation Date: July 31, 2026 Company telephone number: (904) 300-0701

3 metrics

Board notification date July 7, 2026 Date Dr. James J. Ferguson III informed the Board of his decision to resign as Chief Medical Officer

Separation Date July 31, 2026 Effective date of Dr. Ferguson’s resignation as Chief Medical Officer

Company telephone number (904) 300-0701 Registrant’s telephone number listed for Cadrenal Therapeutics, Inc.

Key Terms

Chief Medical Officer, Emerging growth company, separation agreement and release

3 terms

Chief Medical Officer technical

"James J. Ferguson III, Chief Medical Officer of Cadrenal Therapeutics, Inc."

A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

separation agreement and release financial

"intend to enter into a separation agreement and release at a future date"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

Available on EDGAR 07/10/2026 - 04:05 PM Accepted by SEC EDGAR 07/10/2026 - 04:05 PM

FAQ

What leadership change did Cadrenal Therapeutics (CVKD) disclose?

Cadrenal Therapeutics disclosed that Chief Medical Officer Dr. James J. Ferguson III will resign. He informed the Board on July 7, 2026, and will leave effective July 31, 2026, creating a senior medical leadership transition.

When is the Chief Medical Officer’s separation date at Cadrenal Therapeutics (CVKD)?

The separation date for Cadrenal’s Chief Medical Officer is July 31, 2026. Dr. James J. Ferguson III will continue in his role until that date, after which his resignation becomes effective.

Is Cadrenal Therapeutics (CVKD) searching for a new Chief Medical Officer?

Yes, Cadrenal is conducting a search for a new Chief Medical Officer. The company stated it is in the process of identifying Dr. James J. Ferguson III’s replacement following his planned July 31, 2026 separation.

Will Cadrenal Therapeutics (CVKD) enter a separation agreement with its departing CMO?

Cadrenal and Dr. Ferguson plan to enter a separation agreement and release. They are currently negotiating separation terms and intend to finalize a formal agreement at a future date.

What role did Dr. James J. Ferguson III hold at Cadrenal Therapeutics (CVKD)?

Dr. James J. Ferguson III served as Chief Medical Officer of Cadrenal Therapeutics. He oversaw the company’s medical and clinical activities prior to notifying the Board of his decision to resign effective July 31, 2026.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): July 7, 2026

Cadrenal Therapeutics, Inc.

(Exact name of registrant as specified in charter)

Delaware		001-41596		88-0860746
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

822 A1A North, Suite 306

Ponte Vedra, Florida 32082

(Address of principal executive offices and zip code)

(904) 300-0701

(Registrant’s telephone number including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions (see General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbols		Name of each exchange on which registered
Common Stock, par value $0.001 per share		CVKD		The Nasdaq Stock Market LLC (Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 7, 2026, James J. Ferguson III, Chief Medical Officer of Cadrenal Therapeutics, Inc. (the “Company”), advised the Board of Directors of the Company of his decision to resign from his position as Chief Medical Officer of the Company, effective July 31, 2026 (the “Separation Date”). The Company is in the process of conducting a search for Dr. Ferguson’s replacement. The Company and Dr. Ferguson are negotiating the terms of separation and intend to enter into a separation agreement and release at a future date.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are furnished with this Current Report on Form 8-K:

Exhibit Number		Exhibit Description
104		Cover Page Interactive Data File (the cover page XBRL tags are embedded within in the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: July 10, 2026	CADRENAL THERAPEUTICS, INC.

	By:	/s/ Quang X. Pham
	Name:	Quang X. Pham
	Title:	Chairman and Chief Executive Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents